Role of interstitial ATP and adenosine in the regulation of renal hemodynamics and microvascular function

Hypertension Research

Volumn 27, Issue 11, 2004, Pages 791-804

  Nishiyama, Akira ^a   Rahman, Matlubur ^a   Inscho, Edward W ^b  

^a KAGAWA UNIVERSITY   (Japan)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Adenosine; ATP; Renal hemodynamics; Renal microcirculation; Tubuloglomerular feedback (TGF) mechanism

Indexed keywords

1 [3 (2 PHENYLPYRAZOLO[1,5 A]PYRIDIN 3 YL)ACRYLOYL]PIPERIDINE 2 ACETIC ACID; 5 IODOTUBERCIDIN; 8 (2 NOR 1 ADAMANTYL) 1,3 DIPROPYLXANTHINE; 9 (2 HYDROXY 3 NONYL)ADENINE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATE; ALPHA,BETA METHYLENEADENOSINE TRIPHOSPHATE; ANGIOTENSIN; BETA,GAMMA METHYLENEADENOSINE TRIPHOSPHATE; CALCIUM; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; HYPOXANTHINE; INOSINE; LIPOPOLYSACCHARIDE; NORADRENALIN; PHOSPHOLIPASE C; PURINE P2 RECEPTOR; PURINE P2X RECEPTOR; PURINE P2X1 RECEPTOR; PURINE P2Y RECEPTOR; SODIUM CHLORIDE; SURAMIN; UNINDEXED DRUG;

AUTOREGULATION; CALCIUM CELL LEVEL; CELL ISOLATION; CELL TRANSPORT; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; INTERSTITIAL FLUID; KIDNEY BLOOD FLOW; KIDNEY EPITHELIUM; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY INTERSTITIUM; KIDNEY ISCHEMIA; MESANGIUM CELL; MICROCIRCULATION; MICROVASCULARIZATION; NEPHRON; NONHUMAN; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; RECEPTOR BINDING; RENOVASCULAR HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ADENOSINE; ADENOSINE TRIPHOSPHATE; ANIMALS; FEEDBACK, BIOCHEMICAL; HUMANS; KIDNEY; MICROCIRCULATION; RENAL CIRCULATION;

EID: 14644431742     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.27.791     Document Type: Review

References (127)

1. Drury AN, Szent-Györgyi A: The physiological activity of adenine compounds with special reference to their action upon the mammalian heart. J Physiol (Lond) 1929; 68: 213-237.
2. Abbracchio MP, Burnstock G: Purinoceptors: are there families of P2X and P2Y purinoceptors? Pharmacol Ther 1994; 64: 445-475.
3. Inscho EW: P2 receptors in the regulation of renal microvascular function. Am J Physiol Renal Physiol 2001; 280: F927-F944.
4. Barnard EA, Simon J, Webb TE: Nucleotide receptors in the nervous system - an abundant component using diverse transduction mechanisms. Mol Neurobiol 1997; 15: 103-129.
5. 1 purinoceptors by autoradiography and immunohistochemistry in the rat kidney. Am J Physiol Renal Physiol 1998; 274: F799-F804.
6. Di Virgilio F, Ferrari D, Chiozzi P, et al: Purinoceptor function in the immune system. Drug Dev Res 1996; 39: 319-329.
7. Henning RH: Purinoceptors in neuromuscular transmission. Pharmacol Ther 1997; 74: 115-128.
8. 2 receptor subtypes in the cardiovascular system. Biochem J 1998; 336: 513-523.
9. Ralevic V, Burnstock G: Receptors for purines and pyrimidines. Pharmacol Rev 1998; 50: 413-492.
10. Vassort G: Adenosine 5′-triphosphate: a P2-purinergic agonist in the myocardium. Physiol Rev 2001; 81: 767-806.
11. Kawabata H, Ishikawa K: Cardioprotection by metformin is abolished by a nitric oxlide synthase inhibitor in ischemic rabbit hearts. Hypertens Res 2003; 26: 107-110.
12. Harvey RB: Effects of adenosinetriphosphate on autoregulation of renal blood flow and glomerular filtration rate. Circ Res 1964; 14(Suppl 1): I-178-I-182.
13. Carmines PK, Inscho EW: Renal arteriolar angiotensin responses during varied adenosine receptor activation. Hypertension 1994; 23: I-114-I-119.
14. Inscho EW, Ohishi K, Navar LG: Effects of ATP on pre-and postglomerular juxtamedullary microvasculature. Am J Physiol 1992; 263: F886-F893.
15. 2 purinergic stimulation. Hypertension 1991; 17: 1033-1037.
16. Inscho EW, LeBlanc EA, Pham BT, White SM, Imig JD: Purinoceptor-mediated calcium signaling in preglomerular smooth muscle cells. Hypertension 1999; 33: 195-200.
17. Inscho EW, Cook AK: P2 receptor-mediated afferent arteriolar vasoconstriction during calcium channel blockade. Am J Physiol Renal Physiol 2002; 282: F245-F255.
18. 2a receptors on renal microvascular reactivity. Am J Physiol Renal Physiol 2001; 280: F406-F414.
19. 1 receptors in renal microvascular autoregulatory behavior. J Clin Invest 2003; 112: 1895-1905.
20. 1 receptor in angiotensin II-and norepinephrine-induced renal vasoconstriction. J Pharmacol Exp Ther 2002; 303: 117-123.
21. Nishiyama A, Navar LG: ATP mediates tubuloglomerular feedback. Am J Physiol Regul Integr Comp Physiol 2002; 283: R273-R275; discussion, R278-R279.
22. Navar LG, Inscho EW, Majid DSA, Imig JD, Harrison-Bernard LM, Mitchell KD: Paracrine regulation of the renal microcirculation. Physiol Rev 1996; 76: 425-536.
23. Nishiyama A, Majid DSA, Taher KA, Miyatake A, Navar LG: Relation between renal interstitial ATP concentrations and autoregulation-mediated changes in renal vascular resistance. Circ Res 2000; 86: 656-662.
24. White SM, Imig JD, Inscho EW: Calcium signaling pathways utilized by P2X receptors in preglomerular vascular smooth muscle cells. Am J Physiol Renal Physiol 2001; 280: F1054-F1061.
25. Zhao XY, Inscho EW, Bondlela M, Falck JR, Imig JD: The CYP450 hydroxylase pathway contributes to P2X receptor-mediated afferent arteriolar vasoconstriction. Am J Physiol Heart Circ Physiol 2001; 281: H2089-H2096.
26. Majid DSA, Inscho EW, Navar LG: P2 purinoceptor saturation by adenosine triphosphate impairs renal autoregulation in dogs. J Am Soc Nephrol 1999; 10: 492-498.
27. 2-purinoceptor activation. Am J Physiol 1996; 271: F1077-F1085.
28. Nishiyama A, Majid DSA, Walker M III, Miyatake A, Navar LG: Renal interstitial ATP responses to changes in arterial pressure during alterations in tubuloglomerular feedback activity. Hypertension 2001; 37: 753-759.
29. Nishiyama A, Kimura S, He H, et al: Renal interstitial adenosine metabolism during ischemia in dogs. Am J Physiol Renal Physiol 2001; 280: F231-F238.
30. Nishiyama A, Miura K, Miyatake A, et al: Renal interstitial concentration of adenosine during endotoxin shock. Eur J Pharmacol l999; 385: 209-216.
31. 1 receptor antagonist KW-3902 prevents hypoxia-induced renal vasoconstriction. J Pharmacol Exp Ther 1999; 291: 988-993.
32. Nishiyama A, Kimura S, Fukui T, et al: Blood flow-dependent changes in renal interstitial cyclic guanosine 3′,5′-monophosphate in rabbits. Am J Physiol Renal Physiol 2002; 282: F238-F244.
33. Nishiyama A, Miyatake A, Kusudo K, et al: Effects of halothane on renal hemodynamics and interstitial nitric oxide in rabbits. Eur J Pharmacol 1999; 367: 299-306.
34. Nishiyama A, Seth DM, Navar LG: Renal interstitial fluid concentrations Ang II concentrations during local ACE inhibition. J Am Soc Nephrol 2002; 13: 2207-2212.
35. Nishiyama A, Seth DM, Navar LG: Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension 2002; 39: 129-134.
36. 1 receptor-mediated accumulation of renal interstitial angiotensin II in angiotensin II-induced hypertensive rats. J Hypertens 2003; 21: 1897-1903.
37. Burnstock G: Purinoceptors: ontogeny and phylogeny. Drug Dev Res 1996; 39: 204-242.
38. Communi D, Boeynaems JM: Receptors responsive to extracellular pyrimidine nucleotides. Trends Pharmacol Sci 1997; 18: 83-86.
39. 2-purinergic receptors: subtype-associated signaling responses and structure. Annu Rev Pharmacol Toxicol 1995; 35: 541-579.
40. 2X purinoceptors be classified pharmacologically? Trends Pharmacol Sci 1995; 16: 168-174.
41. Fredholm BB, Arslan C, Kull B, Kontny E, Svenningsson P: Adenosine (P1) receptor signalling. Drug Dev Res 1996; 39: 262-268.
42. Fredholm BB, Abbracchio MP, Burnstock G, et al: Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci 1997; 18: 79-82.
43. 2A receptors. Trends Pharmacol Sci 1996; 17: 364-372.
44. Olsson RA: Adenosine receptors in the cardiovascular system. Drug Dev Res 1996; 39: 301-307.
45. North RA, Surprenant A: Pharmacology of cloned P2X receptors. Annu Rev Pharmacol Toxicol 2000; 40: 563-580.
46. North RA: Molecular pharmacology of P2X receptors. Physiol Rev 2002; 82: 1013-1067.
47. 3 adenosine receptors: protective vs. damaging effects identified using novel agonists and antagonists. Drug Dev Res 1998; 45: 113-124.
48. Jackson EK: P1 and P2 receptors in the renal system, in Abbracchio MP, Williams M (eds): Handbook of Experimental Pharmacology. New York, Springer-Verlag, 2001, pp 33-71.
49. Hansen PB, Castrop H, Briggs J, Schnermann J: Adenosine induces vasoconstriction through Gi-dependent activation of phospholipase C in isolated perfused afferent arterioles of mice. J Am Soc Nephrol 2003; 14: 2457-2465.
50. 3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci 1998; 19: 184-191.
51. 3 receptors in the rat: assessment of functional role. Can J Physiol Pharmacol 2000; 78: 428-432.
52. Jackson EK, Zhu C, Tofovic SP: Expression of adenosine receptors in the preglomerular microcirculation. Am J Physiol Renal Physiol 2002; 283: F41-F51.
53. Burnstock G: A basis for distinguishing two types of purinergic receptor, in Bolis L, Straub RCO (eds): Cell Membrane Receptors for Drugs and Hormones; A Multi-disciplinary Approach. New York, Raven Press, 1978, pp 107-118.
54. Burnstock G: Purinergic nerves. Pharmacol Rev 1972; 24: 509-581.
55. Fredholm BB, Abbracchio MP, Burnstock G, et al: Nomenclature and classification of purinoceptors. Pharmacol Rev 1994; 46: 143-156.
56. Evans RJ, Surprenant A, North RA: P2X receptors: cloned and expressed, in Turner JT, Weisman GH, Fedan JS (eds): The P2 Nucleotide Receptors. Totowa, Humana Press Inc., 1998, pp 43-61.
57. El-Moatassim C, Dornand J, Mani JC: Extracellular ATP and cell signalling. Biochim Biophys Acta 1992; 1134: 31-45.
58. 2-purinergic receptors for extracellular ATP and other nucleotides. Am J Physiol 1993; 265: C577-C606.
59. 2x receptor for extracellular ATP. Nature 1994; 371: 516-519.
60. Communi D, Janssens R, Suarez-Huerta N, Robaye B, Boeynaems JM: Advances in signalling by extracellular nucleotides: the role and transduction mechanisms of P2Y receptors. Cell Signal 2000; 12 351-360.
61. Communi D, Govaerts C, Parmentier M, Boeynaems JM: Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. J Biol Chem 1997; 272: 31969-31973.
62. Torres B, Zambon AC, Insel PA: P2Y11 receptors activate adenylyl cyclase and contribute to nucleotide-promoted cAMP formation in MDCK-D1 cells: a mechanism for nucleotide-mediated autocrine-paracrine regulation. J Biol Chem 2002; 277: 7761-7765.
63. Dubyak GR: Knock-out mice reveal tissue-specific roles of P2Y receptor subtypes in different epithelia. Mol Pharmacol 2003; 63 773-776.
64. Abbracchio MP, Boeynaems JM, Barnard EA, et al: Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family. Trends Pharmacol Sci 2003; 24: 52-55.
65. Schwiebert EM, Zsembery A: Extracellular ATP as a signaling molecule for epithelial cells. Biochim Biophys Acta 2003; 1615 7-32.
66. Aki Y, Shoji T, Hasui K, et al: Intrarenal vascular sites of action of adenosine and glucagon. Jpn J Pharmacol 1990; 54: 433-440.
67. Aki Y, Tomohiro A, Nishiyama A, Kiyomoto K, Kimura S, Abe Y: Effects of KW-3902, a selective and potent adenosine A1 receptor antagonist, on renal hemodynamics and urine formation in anesthetized dogs. Pharmacology 1997; 55: 193-201.
68. Churchill PC, Bidani AK: Hypothesis: adenosine mediates hemodynamic changes in renal failure. Med Hypothesis 1983; 8: 275-285.
69. Miura K, Okumura M, Yamanaka S, Kim S, Iwao H: Effects of activation of renal adenosine A2 receptor on renal function and renin release in dogs. Jpn J Pharmacol 1999; 80: 173-176.
70. Spielman WS, Thompson CI: A proposed role for adenosine in the regulation of renal hemodynamics and renin release. Am J Physiol 1982; 242: F423-F435.
71. Harvey RB: Effects of adenosinetriphosphate on autoregulation of renal blood flow and glomerular filtration rate. Circ Res 1964; 15(Suppl): 178-182.
72. Tagawa H, Vander AJ: Effects of adenosine compounds on renal function and renin secretion in dogs. Circ Res 1970; 26: 327-338.
73. Needleman P, Minkes MS, Douglas JR: Stimulation of prostaglandin biosynthesis by adenine nucleotides: profile of prostaglandin release by perfused organs. Circ Res 1970; 34: 455-460.
74. Schor N, Brenner BM: Possible mechanism of prostaglandin-induced renal vasoconstriction in the rat.Hypertension 1981; 3: II-81-II-85.
75. Sakai K, Akima M, Nabata H: A possible purinergic mechanism for reactive ischemia in isolated, cross-circulated rat kidney. Jpn J Pharmacol 1979; 29: 235-242.
76. Churchill PC, Ellis VR: Pharmacological characterization of the renovascular P2 purinergic receptors. J Pharmacol Exp Ther 1993; 265: 334-338.
77. Hansen PB, J Schnermann: Vasoconstrictor and vasodilator effects of adenosine in the kidney. Am J Physiol Renal Physiol 2003; 285: F590-F599.
78. Joyner WL, Mohama RE, Myers TO, Gilmore JP: The selective response to adenosine of renal microvessels from hamster explants. Microvasc Res 1988; 35: 122-131.
79. Gabriëls G, Endlich K, Rahn KH, Schlatter E, Steinhausen M: In vivo effects of diadenosine polyphosphates on rat renal microcirculation. Kidney Int 2000; 57: 2476-2484.
80. Weihprecht H, Lorenz JN, Briggs JP, Schnermann J: Vasomotor effects of purinergic agonists in isolated rabbit afferent arterioles. Am J Physiol 1992; 263: F1026-F1033.
81. Ueda J: Adenine nucleotides and renal function: special reference with intrarenal distribution of blood flow. Jpn J Pharmacol 1972; 22: 5.
82. Spielman WS, Britton SL, Fiksen-Olsen MJ: Effect of adenosine on the distribution of renal blood flow in dogs. Circ Res 1980; 46: 449-456.
83. Dinour D, Brezis M: Effects of adenosine on intrarenal oxygenation. Am J Physiol 1991; 261: F787-F791.
84. 2 receptor. J Pharmacol Exp Ther 1991; 257: 1013-1019.
85. 2 receptor. J Pharmacol Exp Ther 1991; 257: 1005-1012.
86. Inscho EW, Cook AK, Mui V, Miller J: Direct assessment of renal microvascular responses to P2-purinoceptor agonists. Am J Physiol Renal Physiol 1998; 274: F718-F727.
87. 2 purinoceptors in the rat isolated perfused kidney. Pflügers Arch 1996; 306: 139-152.
88. Wang T, Kawabata M, Haneda M, Takabatake T: Effects of uroguanylin, an intestinal natriuretic peptide, on tubuloglomerular feedback. Hypertens Res 2003; 26: 577-582.
89. Schnermann J: Adenosine mediates tubuloglomerular feedback. Am J Physiol Regul Integr Comp Physiol 2002; 283: R276-R277; discussion, R278-R279.
90. Schnermann J, Weihprecht H, Briggs JP: Inhibition of tubuloglomerular feedback during adenosinel receptor blockade. Am J Physiol 1990; 258: F553-F561.
91. Franco M, Bell PD, Navar LG: Effect of adenosine A1 analogue on tubuloglomerular feedback mechanism. Am J Physiol 1989; 257 F231-F236.
92. Brown R, Ollerstam A, Johansson B, et al: Abolished tubuloglomerular feedback and increased plasma renin in adenosine A(1) receptor-deficient mice. Am J Physiol Regul Integr Comp Physiol 2001; 281: R1362-R1367.
93. Sun D, Samuelson LC, Yang T, et al: Mediation of tubuloglomerular feedback by adenosine: evidence from mice lacking adenosine 1 receptors. Proc Natl Acad Sci USA 2001; 98: 9983-9988.
94. Ibarrola AM, Inscho EW, Vari RC, Navar LG: Influence of adenosine receptor blockade on renal function and renal autoregulation. J Am Soc Nephrol 1991; 2: 991-999.
95. Premen AJ, Hall JE, Mizelle HL, Cornell JE: Maintenance of renal autoregulation during infusion of aminophylline or adenosine. Am J Physiol 1985; 248: F366-F373.
96. Silldorff EP, Kreisberg MS, Pallone TL: Adenosine modulates vasomotor tone in outer medullary descending vasa recta of the rat. J Clin Invest 1996; 98: 18-23.
97. Walker M III, Harrison-Bernard LM, Cook AC, Navar LG: Dynamic interaction between myogenic and TGF mechanisms in afferent arteriolar blood flow autoregulation. Am J Physiol Renal Physiol 2000; 279 F858-F865.
98. Ren Y, Garvin JL, Carretero OA: Efferent arteriole tubuloglomerular feedback in the renal nephron. Kidney Int 2001; 59: 222-229.
99. Ren Y, Arima S, Carretero OA, Ito S: Possible role of adenosine in macula densa control of glomerular hemodynamics. Kidney Int 2002; 61: 169-176.
100. Kawabata M, Haneda M, Wang T, Imai M, Takabatake T: Effects of a nucleoside transporter inhibitor, dilazep, on renal microcirculation in rats. Hypertens Res 2002; 25: 615-621.
101. Inscho EW, Ohishi K, Cook AK, Belott TP, Navar LG: Calcium activation mechanisms in the renal microvascular response to extracellular ATP. Am J Physiol 1995; 268: F876-F884.
102. Inscho EW, Mitchell KD, Navar LG: Extracellular ATP in the regulation of renal microvascular function. FASEB J 1994; 8: 319-328.
103. Mitchell KD, Navar LG: Modulation of tubuloglomerular feedback responsiveness by extracellular ATP. Am J Physiol 1993; 264: F458-F466.
104. Schnermann J, Marver D: ATPase activity in macula densa cells of the rabbit kidney. Pflügers Arch 1986; 407: 82-86.
105. Bell PD, Lapointe JY, Sabirov R, et al: Macula densa cell signaling involves ATP release through a maxi anion channel. Proc Natl Acad Sci USA 2003; 100: 4322-4327.
106. Baranowski RL, Westenfelder C: Estimation of renal interstitial adenosine and purine metabolites by microdialysis. Am J Physiol 1994; 267: F174-F182.
107. Siragy HM, Linden J: Sodium intake markedly alters renal interstitial fluid adenosine. Hypertension 1996; 27: 404-407.
108. Zou AP, Nithipatikom K, Li PL, Cowley AW Jr: Role of renal medullary adenosine in the control of blood flow and sodium excretion. Am J Physiol Regul Integr Comp Physiol 1999; 276: R790-R798.
109. Zager RA, Gmur DJ, Bredl CR, Eng MJ, Fisher L: Regional responses within the kidney to ischemia: assessment of adenine nucleotide and catabolite profiles. Biochim Biophys Acta 1990; 1035: 29-36.
110. Ekland T, Wahlberg J, Ungerstedt U, Hillered L: Interstitial lactate inosine and hypoxanthine in rat kidney during normothermic ischaemia and recirculation. Acta Physiol Scand 1991; 143: 279-286.
111. Lutz PL, Kabler S: Release of adenosine and ATP in the brain of the freshwater turtle (Trachemys scripta) during long-term anoxia. Brain Res 1997; 769: 281-286.
112. Kuzmin AI, Lakomkin VL, Kapelko VI, Vassort G: Interstitial ATP level and degradation in control and postmyocardial infarcted rats. Am J Physiol 1998; 275: C766-C771.
113. Miller WL, Thames DA, Berne RM: Adenosine production in the ischemic kidney. Circ Res 1978; 93: 390-397.
114. Osswald H, Schmitz HJ, Kemper R: Tissue content of adenosine, inosine and hypoxanthine in the rat kidney after ischemia and postischemic recirculation. Pflügers Arch 1977; 371: 45-49.
115. Zou AP, Wu F, Li PL, Cowley AW Jr: Effect of chronic salt loading on adenosine metabolism and receptor expression in renal cortex and medulla in rats. Hypertension 1999; 33: 511-516.
116. Knight RJ, Collis MG, Yates MS, Bowmer CJ: Amelioration of cisplatin-induced acute renal failure with 8-cyclopentyl-1,3-dipropylxanthine. Br J Pharmacol 1991; 104: 1062-1068.
117. Bidani AK, Churchill PC: Aminophylline ameliorates glycerol-induced acute renal failure in rats. Can J Physiol Pharmacol 1983; 61: 567-571.
118. Lin JJ, Churchill PC, Bidani AK: Effect of theophylline on the initiation phase of postischemic acute renal failure in rats. J Lab Clin Med 1986; 108: 150-154.
119. Chan CM, Unwin RJ, Burnstock G: Potential functional roles of extracellular ATP in kidney and urinary tract. Exp Nephrol 1998; 6: 200-207.
120. Abbracchio MP, Burnstock G: Purinergic signalling: pathophysiological roles. Jpn J Pharmacol 1998; 78: 113-145.
121. Sauer H, Klimm B, Hescheler J, Wartenberg M: Activation of p90RSK and growth stimulation of multicellular tumor spheroids are dependent on reactive oxygen species generated after purinergic receptor stimulation by ATP. FASEB J 2001; 15: 2539-2541.
122. Poelstra K, Heynen ER, Baller JF, Hardonk MJ, Bakker WW: Modulation of anti-Thy1 nephritis in the rat by adenine nucleotides: evidence for an anti-inflammatory role for nucleotidases. Lab Invest 1992; 66: 555-563.
123. Zoja C, Remuzzi G: Role of platelets in progressive glomerular diseases. Pediatr Nephrol 1995; 9: 495-502.
124. Clark WF, Naylor CD: The role of platelets in progressive glomerulosclerosis: mechanisms for intraglomerular platelet activation and pathogenetic consequences. Med Hypotheses 1989; 28: 51-56.
125. Williams D, Neild GH, Burnstock G: Cyclosporin A increases vascular resistance in the isolated perfused kidney through purinergic mechanisms. Nephrol Dial Transplant 1995; 10: 743-744 (Abstract).
126. Gottlieb SS, Brater DC, Thomas I, et al: BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002; 105: 1348-1353.
127. Gottlieb SS, Skettino SL, Wolff A, et al: Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J Am Coll Cardiol 2000; 35: 56-59.